|  |  |
| --- | --- |
|  | LC and LCMS Demo and AnalysisSample Information |

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Customer Information | | | | | | | | | | |
| company: | | | | | name: | | | | | |
| **Contact** | | | | | phone |  | | | | |
| street | | | | | email |  | | | | |
|  | | | | | Is this a tender? | |  | yes |  | no |
| zip |  | | city |  | Can we use a partner lab? | |  | yes |  | no |
| country | | UK | | | CDA required? | |  | yes |  | no |

|  |
| --- |
| Instrument Demo Objectives |
| Please provide us information about the analysis and key expectations of the customer.   |  |  |  |  |  | | --- | --- | --- | --- | --- | | **Samples description**:  **QC**: quality control **ST0**: susceptible line extract **RT0**: resistant line extract  A blank of extraction (**ExBlk**) will be also provided if required. LC and MS protocols provided in additional document.  **Objectives:**   * determine number of chemical features * Metabolomics workflow software: peak alignment, peak picking, statistics, etc. * differential metabolites between RT0 and ST0 * sensitivity (perform serial dilutions of QC) * Compound ID: identification of differential metabolites between RT0 and ST0 | | | | | | **Presentation of the data:** | Demo | Report | Webex | Zoom Video |  |  | | --- | | Instrument Information | | |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | **Type of instrument to be evaluated:** | | | **Model#:** | | | | | | | | | | | | | | |  | | | 6420 | | | 6460 | | 6470 | | 6495 | | | Ultivo | | |  | | QQQ | | |  | | |  | |  | |  | | |  | | |  | |  | | | 6530 | | | 6545 | | 6550 | | 6560 | | | 6545XT | | |  | | QTOF | | |  | | |  | |  | |  | | |  | | |  | |  | | | MSD | | | MSD XT | |  | |  | | |  | | |  | | SQ | | |  | | |  | |  | |  | | |  | | |  | |  | | | 6230 | | |  | |  | |  | | |  | | |  | | TOF | | |  | | |  | |  | |  | | |  | | |  | |  | 1260 | Prime | | 1290 | CE | | SFC | | Online SPE | | Rapidfire | | | Nano | Automation | | | Separation |  |  | |  |  | |  | |  | |  | | |  |  | | | If desired Model is not available, can we perform analysis on an alternative instrument?  (e.g. 6460 with ESI instead of 6420, QTOF in MS mode instead of TOF) | | | | | | | | | | | | yes  no  If yes, Model#: | | | | | |      |  | | --- | | Please return this form to | |  | |
| Silke Seifert, Agilent Technologies Sales & Services GmbH & Co. KG, Hewlett-Packard-Str. 8, 76337 Waldbronn, Germany |
| phone +49 7243 6022672, e-mail [silke\_seifert@agilent.com](mailto:silke_seifert@agilent.com) |

Application #1 Does a method exist for this application? ☐ yes ☐ no

(You can attach method information provided by the customer, but please add missing information in this table)

|  |
| --- |
| Sample Set Information |
| |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | **Analyte Class Name** |  | | | | | | | | | | **Matrix** |  | | | **Estimate # of injection (total)** | | | | |  | | **Number of Samples** |  | **Amount per sample (mL/mg)** | | | | |  | | | | **Customer is going to provide all standards (individual if possible)?** | | | | | ☐ yes | | ☐ no | | | | **Concentration** |  | **Solvent (if solid for dissolution)** | | | | |  | | | | **Storage conditions** | Freezer | Fridge | | | | Room Temperature | | | | |  |  |  | | | | |  | | | | **Compound name** | **Formula and/or CAS** | | **m/z (+ or -) or MRM trans.** | | | | | **Concentration** | | |  |  | |  | | | | |  | | |  |  | |  | | | | |  | | |  |  | |  | | | | |  | | |  |  | |  | | | | |  | | |  |  | |  | | | | |  | | |  |  | |  | | | | |  | | |  |  | |  | | | | |  | | |  |  | |  | | | | |  | | |

|  |
| --- |
| LC Method Information |
| |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | | **Column** (name, phase, length x diameter, µm): |  | | | | | | |  |  | | **Parameter can be modified:** | | | | | **Column** |  | |  | yes |  | no | | **Column Temperature** |  | |  | yes |  | no | | **Mobile Phase A** |  | |  | yes |  | no | | **Mobile Phase B** |  | |  | yes |  | no | | **Flow rate** |  | |  | yes |  | no | | **Injection volume** |  | |  | yes |  | no | |  | | |  | | | | | **Gradient** | **Time (min)** | **%B** | **Flow** | | | | | **0** |  |  | | | | | **1** |  |  | | | | |  |  |  | | | | |  |  |  | | | | |  |  |  | | | | |  |  |  | | | | |  |  |  | | | | |  |  |  | | | | |  |  |  | | | | | **Other Information**  (e.g. restrictions when modifying parameters, other detectors required) |  | | | | | | |
| MS Method Information |
| |  |  |  |  |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | **Ion Source** | Jet Stream | ESI | | APCI | | APPI | | Multi Mode | | Nano | |  |  |  | |  | |  | |  | |  | |  | | | | | |  |  |  |  |  | | **Polarity** | |  | positive |  | negative |  | Fast polarity switching | | | | |  | | | | | | | | | | | | **Specific acquisition modes that need to be demonstrated** (e.g. QQQ: triggered MRM, QTOF: All Ions)? | | | | | | | | | | | | QTOF, full scan and MS/MS | | | | | | | | | | | |

|  |
| --- |
| Software and Workflows |
| |  |  |  |  |  |  |  | | --- | --- | --- | --- | --- | --- | --- | | **Please specify software or workflows that have been positioned with the customer or that you would like us to present during the demo:** | | | | | | | | Metabolomics: untargeted analysis (chemical fingerprinting) and targeted analysis, ID and annotation of compounds, libraries | | | | | | | | For screening workflows, please specify: |  | Target |  | Suspect |  | Discovery | |

|  |
| --- |
| Other Information |
| |  | | --- | | **Please share with us any other information that might help us to qualify the project and perform a better demo or sample measurement:** | | Please refer to “Instrument Demo Objectives” section and additional documents supplied | |

**Tips for your customer’s instrument evaluation:**

* Explain the objective of the instrument evaluation in your own words, summarize in a few sentences.
* Ask your customer to
  + use samples and analytes that they know and understand. Even when evaluating discovery workflows (analysis of unknown compounds).
  + avoid redundancy and to choose a small number of meaningful analytes and samples. A too large number of analytes and samples will consume a lot of time and impede the presentation of all key features of the instrument and the software.
  + design the tests in a way that their routine challenges can be addressed rather than rechecking instrument specifications.